Skye Financial Statements From 2010 to 2024

SKYE Stock  USD 2.86  0.15  4.98%   
Skye Bioscience, financial statements provide useful quarterly and yearly information to potential Skye Bioscience, Common investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Skye Bioscience, financial statements helps investors assess Skye Bioscience,'s valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Skye Bioscience,'s valuation are summarized below:
Market Capitalization
163.5 M
Earnings Share
(3.60)
There are over one hundred nineteen available fundamental trend indicators for Skye Bioscience, Common, which can be analyzed over time and compared to other ratios. Investors should ensure to double-check all of Skye Bioscience,'s current performance against the performance from 2010 to 2024 to make sure the company is sustainable down the road. As of December 20, 2024, Market Cap is expected to decline to about 11.3 M. In addition to that, Enterprise Value is expected to decline to about 11.7 M
Check Skye Bioscience, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Skye Bioscience,'s main balance sheet or income statement drivers, such as Interest Expense of 567.6 K, Income Tax Expense of 2.8 K or Tax Provision of 3 K, as well as many indicators such as Price To Sales Ratio of 275, Dividend Yield of 0.0 or Days Sales Outstanding of 29.72. Skye financial statements analysis is a perfect complement when working with Skye Bioscience, Valuation or Volatility modules.
  
Check out the analysis of Skye Bioscience, Correlation against competitors.

Skye Bioscience, Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Other Current Liabilities4.7 M8.3 M2.6 M
Slightly volatile
Total Current Liabilities14.6 M13.9 M4.5 M
Slightly volatile
Accounts Payable653.5 K1.2 M470.3 K
Slightly volatile
Other Assets0.860.918.8 K
Slightly volatile
Other Current Assets10.7 M10.2 M1.5 M
Slightly volatile
Other Stockholder Equity107.4 M102.2 M29.9 M
Slightly volatile
Total Current Assets12.2 M11.7 M3.4 M
Slightly volatile
Common Stock11.7 K12.3 K146.9 K
Slightly volatile
Property Plant Equipment283.4 K269.9 K73.6 K
Slightly volatile
Total AssetsM11.9 M3.2 M
Slightly volatile
Other Liabilities77.6 K81.7 K343.5 K
Slightly volatile
Cash1.2 M1.3 M1.4 M
Slightly volatile
Non Current Assets Total304 K289.6 K68.5 K
Slightly volatile
Common Stock Shares Outstanding6.7 MM73.1 M
Pretty Stable
Non Current Liabilities Total162.7 K171.2 K670.9 K
Very volatile
Total Liabilities8.3 M14.1 M4.7 M
Slightly volatile
Short and Long Term Debt4.6 M4.4 M990.5 K
Slightly volatile
Long Term Debt1.2 M1.6 M1.3 M
Very volatile
Capital Stock11.7 K12.3 K206 K
Slightly volatile
Property Plant And Equipment Net150.5 K281.3 K56.8 K
Slightly volatile
Short and Long Term Debt Total2.8 M4.6 M1.9 M
Slightly volatile
Current Deferred Revenue659.1 KM454.3 K
Slightly volatile
Cash And Short Term Investments1.2 M1.3 M2.7 M
Very volatile
Liabilities And Stockholders Equity9.2 M11.9 M4.6 M
Slightly volatile
Property Plant And Equipment Gross187.6 K281.3 K62.9 K
Slightly volatile
Short Term Debt2.3 M4.4 M764.6 K
Slightly volatile
Net Receivables127.8 K158.2 K83.3 K
Slightly volatile

Skye Bioscience, Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Income Tax Expense2.8 K3.6 K2.2 K
Slightly volatile
Tax ProvisionK3.6 K2.2 K
Slightly volatile
Selling General Administrative5.6 M7.9 M4.4 M
Slightly volatile
Research Development3.1 M5.8 M1.7 M
Slightly volatile
Total Operating Expenses8.6 M13.5 MM
Slightly volatile
Reconciled Depreciation130.5 K124.3 K31.5 K
Slightly volatile
Interest Income105 K100 K15 K
Slightly volatile
Depreciation And Amortization75.7 K124.3 K24.6 K
Slightly volatile
Other Operating Expenses11 M13.7 M7.6 M
Slightly volatile
Cost Of Revenue75.7 K124.3 K24.6 K
Slightly volatile
Selling And Marketing Expenses99.4 K111.8 K121.8 K
Slightly volatile

Skye Bioscience, Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Borrowings626.9 K510 K612.6 K
Very volatile
End Period Cash Flow10.9 M10.3 M2.6 M
Slightly volatile
Begin Period Cash Flow1.2 M1.2 M1.2 M
Slightly volatile
Depreciation130.5 K124.3 K31.5 K
Slightly volatile
Other Non Cash Items24.2 M23.1 M3.8 M
Slightly volatile
Stock Based Compensation763.2 K987.5 K690.4 K
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio275289924
Slightly volatile
Days Sales Outstanding29.7231.2959.8053
Slightly volatile
Average Payables1.4 M1.3 M536.2 K
Slightly volatile
Capex To Depreciation0.0960.1013.6662
Slightly volatile
EV To Sales275289924
Slightly volatile
Payables Turnover0.10.10754.2951
Slightly volatile
Sales General And Administrative To Revenue0.410.35420.3667
Pretty Stable
Average Inventory5.2 K5.9 K6.4 K
Slightly volatile
Capex To Revenue0.110.130.1412
Slightly volatile
Cash Per Share0.170.17935.2907
Pretty Stable
Days Payables Outstanding3.2 K3.4 K10.7 K
Slightly volatile
Current Ratio0.80.83812.4352
Slightly volatile
Receivables Turnover12.6812.0711.6695
Slightly volatile
Graham Number5.766.065253.2643
Pretty Stable
Capex Per Share0.00170.00180.39
Slightly volatile
Average Receivables61.3 K116.2 K44 K
Slightly volatile
Revenue Per Share9.398.948.5731
Slightly volatile
Interest Debt Per Share0.720.75342.6057
Pretty Stable
Debt To Assets0.420.36620.4013
Pretty Stable
Days Of Payables Outstanding3.2 K3.4 K10.7 K
Slightly volatile
Quick Ratio0.850.89252.3977
Slightly volatile
Net Income Per E B T0.951.00013.0457
Slightly volatile
Cash Ratio0.08590.09041.7789
Slightly volatile
Days Of Sales Outstanding29.7231.2959.8053
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.471.00091.7128
Slightly volatile
Fixed Asset Turnover6.877.738.4203
Slightly volatile
Debt Ratio0.420.36620.4013
Pretty Stable
Price Sales Ratio275289924
Slightly volatile
Asset Turnover1.092.11.9741
Slightly volatile
Gross Profit Margin0.70.710.6334
Pretty Stable
Operating Cycle69.2572.991.7467
Slightly volatile

Skye Bioscience, Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap11.3 M17.2 M11.9 M
Slightly volatile
Enterprise Value11.7 M20.2 M12.4 M
Slightly volatile

Skye Fundamental Market Drivers

Cash And Short Term Investments1.3 M

About Skye Bioscience, Financial Statements

Skye Bioscience, stakeholders use historical fundamental indicators, such as Skye Bioscience,'s revenue or net income, to determine how well the company is positioned to perform in the future. Although Skye Bioscience, investors may analyze each financial statement separately, they are all interrelated. For example, changes in Skye Bioscience,'s assets and liabilities are reflected in the revenues and expenses on Skye Bioscience,'s income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Skye Bioscience, Common. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred RevenueM659.1 K
Cost Of Revenue124.3 K75.7 K
Sales General And Administrative To Revenue 0.35  0.41 
Capex To Revenue 0.13  0.11 
Revenue Per Share 8.94  9.39 
Ebit Per Revenue(0.41)(0.39)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Skye Bioscience, Common is a strong investment it is important to analyze Skye Bioscience,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Skye Bioscience,'s future performance. For an informed investment choice regarding Skye Stock, refer to the following important reports:
Check out the analysis of Skye Bioscience, Correlation against competitors.
You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Skye Bioscience,. If investors know Skye will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Skye Bioscience, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.60)
Return On Assets
(0.30)
Return On Equity
(0.55)
The market value of Skye Bioscience, Common is measured differently than its book value, which is the value of Skye that is recorded on the company's balance sheet. Investors also form their own opinion of Skye Bioscience,'s value that differs from its market value or its book value, called intrinsic value, which is Skye Bioscience,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Skye Bioscience,'s market value can be influenced by many factors that don't directly affect Skye Bioscience,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Skye Bioscience,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Skye Bioscience, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Skye Bioscience,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.